TimeScale Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

TimeScale Financial’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$14.2K	Hold	75	–	–	﹤0.01%	328
2023 Q1	$15K	Hold	75	–	–	﹤0.01%	308
2022 Q4	$15K	Hold	75	–	–	﹤0.01%	250
2022 Q3	$15K	Hold	75	–	–	﹤0.01%	248
2022 Q2	$11K	Hold	75	–	–	﹤0.01%	272
2022 Q1	$12K	Buy	+75	New	+$11.4K	﹤0.01%	280

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TimeScale Financial's ALNY Position: Q2 2023 in Review

TimeScale Financial held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2023 at 75 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #328.

TimeScale Financial first reported a position in ALNY in Q1 2022 and has held it in 6 quarters since. The position peaked at $15K in Q1 2023. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

TimeScale Financial held 75 shares of Alnylam Pharmaceuticals worth $14.2K as of Q2 2023.
TimeScale Financial left its Alnylam Pharmaceuticals share count unchanged in Q2 2023.
Alnylam Pharmaceuticals made up ﹤0.01% of TimeScale Financial's portfolio in Q2 2023, its #328 holding.
TimeScale Financial first reported a position in Alnylam Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
TimeScale Financial's Alnylam Pharmaceuticals position peaked at $15K in Q1 2023.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on TimeScale Financial's 13F filing for Q2 2023, filed 27 Jul 2023.